17:22 , Apr 20, 2018 |  BC Week In Review  |  Company News

BMS, JNJ in deal for Factor XIa inhibitor

Bristol-Myers Squibb Co. (NYSE:BMY) and the Janssen Pharmaceuticals Inc. unit of Johnson & Johnson (NYSE:JNJ) partnered to develop and commercialize Factor XIa inhibitors, including BMS-986177. BMS will receive an undisclosed upfront payment and is eligible for...
20:26 , Apr 16, 2018 |  BC Extra  |  Company News

BMS, JNJ in deal for Factor XIa inhibitor

Bristol-Myers Squibb Co. (NYSE:BMY) and the Janssen Pharmaceuticals Inc. unit of Johnson & Johnson (NYSE:JNJ) partnered to develop and commercialize Factor XIa inhibitors, including BMS-986177. BMS will receive an undisclosed upfront payment and is eligible for...